Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Lukas H. Haaksma, Raffaele Palmieri, Jesse M. Tettero, Tom Reuvekamp, Lok Lam Ngai, Costa Bachas, Angèle Kelder, Willemijn J. Scholten, Patrycja Gradowska, Valentina Arena, Anderson Simione, Luca Maurillo, Adriano Venditti, Bob Lowenberg, Gert J. Ossenkoppele, David C. de Leeuw, Maura R. V. Ikoma-Colturato, Francesco Buccisano, Jacqueline Cloos

Blood (2024) 144 (Supplement 1): 4329.

https://doi.org/10.1182/blood-2024-203158

Published: 2024

Journal Articles

Clinical Implications of Central Nervous System Involvement in Acute Myeloid Leukemia

Giovangiacinto Paterno, Flavia Mallegni, Elisa Buzzatti, Maria Irno Consalvo, Elisa Meddi, Federico Moretti, Lucrezia De Marchi, Kristian Taka, Camilla Page, Massimiliano Marinoni, Luca Maurillo, Carmelo Gurnari, Raffaele Palmieri, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe

Blood (2024) 144 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2024-209847

Published: 2024

Journal Articles

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Blood (2023) 142 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2023-190091

Published: 2023

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Blood (2023) 142 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2023-181142

Published: 2023

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis

Alfonso Piciocchi, Valentina Arena, Monica Messina, Sonia Maria Orlando, Raffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, Paola Fazi, Marco Vignetti, Francesco Buccisano, Adriano Venditti

Blood (2022) 140 (Supplement 1): 3192–3193.

https://doi.org/10.1182/blood-2022-158942

Published: 2022

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

Journal Articles

Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia

Raffaele Palmieri, Simona Iacobelli, Giovangiacinto Paterno, Moretti Federico, Elisa Buzzatti, Meddi Elisa, Savi Arianna, Gentiana Trotta, Flavia Mallegni, Maria Ilaria Del Principe, Luca Maurillo, Maria Teresa Voso, Adriano Venditti, Francesco Buccisano

Blood (2022) 140 (Supplement 1): 8961–8962.

https://doi.org/10.1182/blood-2022-159101

Published: 2022

Journal Articles

The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials

Alfonso Piciocchi, Monica Messina, Marta Cipriani, Francesca Paoloni, Giorgia Simonetti, Raffaele Palmieri, Giovanni Marconi, Francesco Buccisano, Paola Fazi, Marco Vignetti, Giovanni Martinelli, Adriano Venditti

Blood (2022) 140 (Supplement 1): 137–138.

https://doi.org/10.1182/blood-2022-158890

Published: 2022

Journal Articles

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

Gabrielle Paras, Linde M. Morsink, Megan Othus, Filippo Milano, Brenda M. Sandmaier, Lucas C. Zarling, Raffaele Palmieri, Gary Schoch, Chris Davis, Marie Bleakley, Mary E. D. Flowers, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, Roland B. Walter

Blood (2022) 139 (11): 1694–1706.

https://doi.org/10.1182/blood.2021014804

Published: 2022

Includes: Supplemental data

Journal Articles

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2359.

https://doi.org/10.1182/blood-2021-147200

Published: 2021

Journal Articles

Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

Raffaele Palmieri, MD, Alfonso Piciocchi, Valentina Arena, MS, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Tiziana Ottone, Mariadomenica Divona, Serena Lavorgna, Maria Irno Consalvo, Consuelo Conti, Cristina Attrotto, Daniela Fraboni, Maria Teresa Voso, MD, William Arcese, MD PhD, Adriano Venditti, MD, Francesco Buccisano, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-139557

Published: 2020

Journal Articles

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-139773

Published: 2020

Journal Articles

Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience

Raffaele Palmieri, MD, Giovangiacinto Paterno, Eleonora De Bellis, Elisa Buzzatti, Valentina Rossi, Ambra Di Veroli, MD, Fabiana Esposito, Lisa Mercante, Carmelo Gurnari, MD, Paola Casciani, Maria Ilaria Del Principe, Luca Maurillo, Maria Teresa Voso, MD, William Arcese, Adriano Venditti, Francesco Buccisano, MD

Blood (2019) 134 (Supplement_1): 2150.

https://doi.org/10.1182/blood-2019-127873

Published: 2019

Journal Articles

Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

Blood (2019) 134 (Supplement_1): 5083.

https://doi.org/10.1182/blood-2019-129184

Published: 2019

Journal Articles

Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Francesco Buccisano, MD, Raffaele Palmieri, MD, Maria Irno Consalvo, Alfonso Piciocchi, Luca Maurillo, Maria Ilaria Del Principe, Valentina Arena, Stefano Soddu, Ambra Di Veroli, MD, Giovangiacinto Paterno, Eleonora De Bellis, Daniela Fraboni, Consuelo Conti, Maria Teresa Voso, MD, William Arcese, Adriano Venditti

Blood (2019) 134 (Supplement_1): 2688.

https://doi.org/10.1182/blood-2019-128025

Published: 2019

Journal Articles

Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 1606.

https://doi.org/10.1182/blood.V130.Suppl_1.1606.1606

Published: 2017

Journal Articles

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Luigi Gugliotta, MD, Alessandra Iurlo, MD, Gabriele Gugliotta, MD PhD, Alessia Tieghi, MD, Lucia Canafoglia, MD, Raffaele Palmieri, MD, Crescenza Pasciolla, MD, Nicola Vianelli, MD, Riccardo Ragionieri, Erminia Rinaldi, MD, Emilio Usala, MD, Giorgio La Nasa, MD, Alessandra Perra, MD, Giuseppe Tagariello, MD, Nilla Maschio, MD, Emma Cacciola, PhD, Rossella Rosaria Cacciola, PhD, Micaela Bergamaschi, MD, Anna Da Col, MD, Angela Rago, MD, Lorenzo Rizzo, MD, Francesco Spina, MD, Daniele Cattaneo, MD, Daniela Lambertenghi, MD, Aniello Casoria, MD, Maria Langella, Maria Luigia Randi, MD, Elisabetta Cosi, MD, Monica Crugnola, MD, Elena Masselli, MD, Paola Ranalli, MD, Giovanni Garozzo, MD, Katia Codeluppi, Oreste Villani, MD, Grazia Ferrara, Cristina Santoro, MD, Potito Rosario Scalzulli, MD, Manlio Ricciotti, MD, Viviana Appolloni, MD, Anna Candoni, MD, Annalisa Luraschi, MD, Rupoli Serena, MD, Mauro DI Ianni, MD, Giovanni Caocci, MD, Francesco Lanza, MD, Nicola Orofino, MD, Elisa Rumi, MD, Alfredo Dragani, MD, Bruno Martino, MD, Anna Marina Liberati, MD, Umberto Santoro, Alessandro M. Vannucchi, MD PhD

Blood (2016) 128 (22): 5472.

https://doi.org/10.1182/blood.V128.22.5472.5472

Published: 2016

NARROW

Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Clinical Implications of Central Nervous System Involvement in Acute Myeloid Leukemia

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia

The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience

Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only